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ABSTRACT 
A link between use of the contraceptive depomedroxyprogesterone acetate and risk of 
HIV-1 acquisition has been demonstrated in epidemiologic studies. Peak medroxyprogesterone-
17-acetate (MPA) levels occur 4 days post-injection with serum progestin levels of 2 nM. 
However, other studies have evaluated its in vitro effects at supraphysiologic concentrations 
resulting in immune modulation of epithelial cell lines and peripheral blood mononuclear cells. 
To formally evaluate MPA effects on HIV-1 infection in a more physiologic model, we utilized 
our polarized ectocervical tissue explant model. Our hypothesis is physiologic concentrations of 
MPA will not affect HIV-1 replication in ectocervical tissue ex vivo.  
Human ectocervical tissue was processed into polarized explants. Explants were cultured 
alone (control) or with MPA in the basolateral compartment at physiological (0.05nM, 0.5nM, 
1nM, 5nM) (n=17) or higher concentrations (500nM, 5µM, 500µM) (n=10) for 48 h, infected 
with either 5x102 or 5x103 TCID50 HIV-1BaL apically for 24 h, and then washed. Basolateral 
supernatants were collected and replenished with fresh medium containing MPA every 3-4 days 
up to 21 days. Supernatant collections at the 48 h time point (pre-infection) were tested for 
cytokine expression while all following supernatant collections post-infection were analyzed for 
viral p24gag concentrations via ELISA.  PBMCs were cultured for 72 hours in media containing 
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MPA at 5µM, 50µM, and500µM (n=5), including a negative and activated control, then analyzed 
for antibodies via flow cytometry.  
Viral replication over 21 days in the presence of supraphysiologic concentrations of MPA 
indicated suppression, while that in the presence of physiologic concentrations was not 
significantly different from the control. Evaluation of cytokine markers indicated a hormone 
dose-dependent relationship between decreasing MPA concentrations (500µM-5nM) and 
increasing expression of pro-inflammatory cytokines approaching levels of the control, which 
were significant for IL-12 (p40), IL6, and IL-8.  
MPA does not significantly affect HIV-1 replication at physiologic concentrations but 
has an overall suppressive effect on replication at supraphysiologic concentrations in 
ectocervical tissue in cervical tissue ex vivo. 
The public health significance of DMPA continuation requires balancing unintended 
pregnancy while diminishing HIV-1 acquisition risk, especially when the risks of infection do 
not outweigh the contraceptive benefits.  
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1.0  INTRODUCTION 
The use of progestin-based hormones as a therapeutic agent provides a range of benefits for 
women, including serving as an effective birth control option [1]. Despite this advantage, 
progestin-based hormones, in particular injectable depo-medroxyprogesterone acetate (DMPA), 
have a suspected epidemiologic risk between use and HIV-1 acquisition [2-4]. In several 
systematic reviews, DMPA users had higher incident HIV-1 seroconversion rates than other 
contraceptives users [2-4]. DMPA has also been linked with immunological suppression by 
diminishing systemic innate and adaptive immunity against HIV-1 replication or acting as a 
steroid inducing a local pro-inflammatory milieu [5-6]. Despite these concerns, use of DMPA is 
still recommended in resource poor countries where contraceptive choice is limited [7]. In 
Africa, and in particular southern Africa, injectable hormonal contraceptives have a high rate of 
use; in 2015, approximately 28.8% of modern contraceptive methods use was injectable [8]. 
Compounding this high usage rate, the region carries a high HIV-1 incidence rate of 0.56 in 
adults [9]. The coupling of a high percentage of injectable contraceptive users with high HIV-1 
prevalence warrants further study on factors driving this epidemiologic relationship. 
Of the two injectable progestin-based contraceptives, DMPA poses the greatest risk for 
HIV-1 acquisition while minimal risk was associated with norethisterone enanthate (NET-EN) 
use [10]. Female sex hormones influence all areas of the female genital tract, but the ectocervix 
or lower reproductive tract seems to be a preferred site for HIV-1 infection due to higher 
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abundance of immune cells, specifically CD4+ T cells, compared to vaginal epithelium [11-12]. 
While serum progestin levels peak at approximately 2nM early after dosage (approximately 4 
days) [13], there is a long drug tail that could influence HIV-1 acquisition risk when serum levels 
reach steady state. Changes in viral chemokine co-receptor expression on T cells may also 
contribute to increased susceptibility. The expression of CCR5, the major HIV-1 coreceptor on 
T-cells, is positively associated with progestin-only contraceptive exposure [14-15]. In addition, 
CD4/CCR5 double-positive cervical T cells experience increased viral infection compared to T 
cell subsets from serum [16]. The higher rates of viral entry with cervical CCR5 combined with 
increased abundance in the presence of a progestin-based contraceptive possibly provides more 
target cells than otherwise would be found if no additional progestin were present, thereby 
facilitating infection. This indicates that DMPA influences the local mucosal immune profile in 
favor of HIV-1 infection. Furthermore, the steroidal activity of synthetic progesterone and its 
higher affinity to the glucocorticoid receptor (GR) than endogenous progesterone plays a role in 
its induction of pro-inflammatory mediators that may facilitate viral infection [17-19]. Ferreira et 
al. observed that HIV-1 exposed genital epithelial cells showed enhanced viral uptake and 
transcytosis in a dose-dependent manner in the presence of DMPA, but this work focused on 
high concentrations of hormone, ranging from 1nM to 100nM, which is above the peak 
physiological level [20]. In yet another in vitro model, a brief high-dose exposure (39-390µM) 
correlated with increased susceptibility to HIV-1 infection [21]. While this information suggests 
DMPA may increase HIV-1 susceptibility in individual epithelial or immune cell models, 
confirmation in a reproducible tissue model that contains the resident immune cells along with 
the intact epithelium and lamina propria instead of individual cells or cell lines is needed so 
mechanisms of MPA related to viral enhancement can be defined. The interplay between the 
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different cell types that are present in a tissue model would be allow for intercellular 
communication. Once established, mechanistic pathways can be pursued to understand how 
MPA may affect HIV-1 infection. 
1.1 EPIDEMIOLOGIC ASSOCIATION 
DMPA and NET-EN are both injectable, progestin-based hormonal contraceptives with differing 
associated observational risks for HIV-1 acquisition among users. While NET-EN portrays no 
significant effect, a meta-analysis of various contraceptive methods on HIV-1 acquisition shows 
that DMPA is more often significantly associated with increased risk but remains contradicted by 
data showing no effect [2]. Heffron et al. demonstrated a seroconversion incidence from HIV-1 
negative women of 6.85 per 100 person-years for those using any hormonal injectable, compared 
to 3.78 for those not any hormonal contraception, and 5.94 for those on oral contraceptive [4]. 
This was supported by an adjusted hazard ratio of 2.05 for injectable hormonal contraceptives 
(95% CI 1.04-4.04). Furthermore, in a study evaluating the differential contributions of DMPA 
versus NET-EN in a group of women that used only one method, DMPA was associated with an 
adjusted hazard ratio of 1.29 for HIV-1 seroconversions compared to the NET-EN reference 
[10]. In a secondary analysis of women enrolled in the Methods for Improving Reproductive 
Health in Africa (MIRA) trial, both DMPA and NET-EN were not significantly associated with 
HIV-1 acquisition (HR 1.18, 95% CI 0.84-1.62; HR 1.40, 95% CI 0.72-2.35) even after 
adjustment for baseline characteristics, but overall, injectables showed significant association 
(HR 1.32, 95% CI 1.00-1.74) [25]. However, Kleinschmidt et al. showed no significant 
difference in HIV-1 acquisition for DMPA users nor NET-EN users compared to those not on 
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any contraceptive [26]. These discrepant results led the World Health Organization (WHO) to 
issue a recommendation in 2012 for HIV-1 negative women to implement male and female 
condom use or other preventive measures as a supplement to injectable progestin contraceptives 
[22]. An updated guideline recommendation in 2017 reaffirms a positive association between 
DMPA use and HIV-1 risk, but cites difficulties in teasing out, “causal relationships versus 
methodological limitations” [23].  
1.2 MECHANISMS FOR HIV-1 ACQUISITION 
1.2.1 Glucocorticoid activity 
DMPA interacts with a wide range of steroid receptors aside from the progesterone receptor (PR) 
[27]. Compared to NET-EN and endogenous progesterone, DMPA exhibits higher affinities for 
the glucocorticoid receptor (GR), leads to greater GR phosphorylation, and has greater protection 
from ligand-receptor degradation [17]. DMPA also displays a higher affinity to the GR than the 
PR (while NET-EN demonstrates the reverse) and competitively binds with the corticosteroid, 
dexamethasone [17, 28]. GR engagement may result in transcription of related factors. In an 
evaluation of MPA on transcription of pro-inflammatory cytokine IL-12 and anti-inflammatory 
cytokine IL-10 in ectocervical cells, increasing concentrations of hormone resulted in increased 
expression of IL-12 and reduced expression of IL-10 via elevated recruitment of the GR to their 
respective promoter regions, compared to cortisol and endogenous progesterone [18, 29]. While 
this experiment was done using 1µM of hormone, physiologic concentrations of DMPA affect 
expression of pro-inflammatory genes in a dose-dependent manner; expression levels of IL-6 and 
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IL-8 in PBMCs gradually decreased as MPA concentrations increased from 1nM to 100nM [29]. 
PBMCs treated with concentrations of MPA at 10,000nM increased IFN-γ expression in the 
presence of a GR antagonist mifepristone compared to MPA lacking the antagonist, confirming 
that the inhibitory cytokine expression through high-dose MPA was mediated by engagement of 
the GR [43].  
 
1.2.2 Local immunological environment 
Synthetic progesterone exposure confers different chemokine/cytokine expression than 
endogenous progesterone exposure. DMPA use has been associated with significant upregulation 
of local female genital tract innate factors, specifically HNP1–3, LL-37, and lactoferrin; cationic 
polypeptides that have implications in recruitment of HIV-1 target cells [6, 30]. Although known 
to have some antiviral capabilities, HNP1 has been shown to facilitate viral migration across the 
epithelial barrier by disrupting tight junctions and increasing permeability [31-32]. LL-37 
exhibits similar antiviral functions but also increases the expression of CD4 and CCR5 co-
receptors in Langerhans Cells [33-34]. Furthermore, the chemokine/cytokine profile of 
cervicovaginal lavages from DMPA users resembles an inflammatory state, with an increase in 
the pro-inflammatory cytokines TNF-α, IL-1α, IL-1β, and IL-6, in addition to adaptive cytokines 
IL-2 and IFN-γ [30].  
 DMPA may facilitate HIV-1 infection by enhancing recruitment of activated target cells to 
the vaginal mucosa. There’s still discrepancies in the literature as some have seen no change in 
CCR5 expression, especially one study where the percent CCR5 positive T cells in PBMCs from 
DMPA users didn’t differ from other contraceptive groups [14], but another noted increased 
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expression of CCR5 after PBMCs were cultured in progesterone [15]. Even exposure to one dose 
of DMPA significantly increased T cell activation markers without significantly altering 
epithelial thickness [35]. Compared to the follicular phase, women who were given one 150mg 
dose of DMPA experienced increased levels of CD45, CD3, CD8, CD68, CCR5, and HLA-DR 
positive vaginal T cells measured at 12 weeks post-injection [35]. Interestingly, neither epithelial 
thickness nor E-cadherin levels (cell adhesion molecule) were significantly altered after DMPA 
treatment compared to the follicular and luteal phases, but the number of Ki-67 positive 
epithelial cells indicating proliferation was significantly increased after DMPA administration 
compared to both phases. This was attributed to the lack of subsequent dosing, leading to 
epithelial regeneration at 12 weeks post-dose. While no changes in epithelial integrity were noted 
in this experiment, DMPA exposure was associated with increased recruitment of target cells to 
the vaginal mucosa.  
Synthetic progesterone in the context of herpes simplex virus-2 (HSV-2) infection plays a 
role in driving the MPA-HIV relationship. South African countries with high HIV-1 prevalence 
are also associated with having a high prevalence of HSV-2; the population attributable fraction 
(PAF) of new HIV-1 infections attributable to HSV-2 is estimated to be 35-50% [46]. Given this 
association, HSV-2 could be a trigger enhancing HIV-1 acquisition. A disrupted mucosal 
permeability resulting from MPA exposure leaves the vaginal mucosa permissive to HSV-2 
infection [36], which also has been demonstrated to induce inflammation at the vaginal mucosa 
[37]. In a study evaluating T-cell activation and T-cell subset numbers in cervical cytobrush 
samples of women, HSV-2 positivity was associated with increased expression of 
CD3/CD4/CCR5 positive and CD69 positive cells compared to HSV-2 negative samples [37]. In 
HSV-2/HIV-1 co-infected ectocervical tissue models, the HSV-2/HIV-1 combination portrayed 
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significantly greater relative CD4/CCR5 expression than HIV-1 alone, and produced 
significantly greater HIV-1 replication [38]. Pre-existing HSV-2 infections create an 
inflammatory environment susceptible to HIV-1infiltration and enhanced replication [39], and 
are heightened with MPA exposure. This is supported epidemiologically as HSV-2 seropositive 
women are twice as likely to seroconvert to HIV-1 when using DMPA, compared to NET-EN 
[10]. However, there remains a gap in our knowledge on the direct effects of MPA on HIV-1 
transmission. Our hypothesis is that physiological levels of MPA will not affect HIV-1 infection 
in mucosal tissue ex vivo. 
 
1.3 EXPERIMENTAL RATIONALE 
To characterize the impact exogenous progestins may have on genital HIV-1 transmission, 
polarized ectocervical tissues were treated with sustained concentrations of MPA and exposed to 
HIV-1 and changes in HIV-1 replication and soluble immune mediators were measured. Because 
of logistical concerns of isolating immune cells from tissue, peripheral blood mononuclear cells 
(PBMCs) were treated with physiologic and supraphysiologic concentrations of MPA to 
understand its effect on CD4+ T-cell surface markers that are important for cellular activation 
and HIV-1 infection. Given the implications of the undescribed long-term effects of DMPA 
combined with previous experiments at various hormone concentrations, we hypothesized that 
physiologic concentrations of DMPA will not affect HIV-1 replication. 
The public health consequence of DMPA continuation requires balancing unintended 
pregnancy while diminishing HIV-1 acquisition risk. Complete discontinuation of DMPA is not 
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recommended as currently the risks of infection do not outweigh the contraceptive benefits, 
especially when compared to relatively less effective methods, condoms alone or oral 
contraceptives [22-24]. Furthermore, it is estimated that a shift from DMPA to oral 
contraceptives would result in 165 additional unwanted births per 100 HIV-1 infections averted 
among serodiscordant couples, but in the same high-risk population would peak to 1276 
additional unwanted births per 100 HIV-1 infections averted if switched to no contraceptive 
method [24]. More research investigating biological mechanisms and linking with 
behavioral/environmental factors is necessary to identify drivers of the DMPA-HIV relationship. 
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2.0  MATERIALS AND METHODS 
2.1 REAGENT PREPARATION 
Unless otherwise stated, all culture media was obtained from Cellgro (Manassas, VA), all media 
supplements were obtained from Gemini BioProducts (West Sacramento, CA), and all antibodies 
for flow cytometry were obtained from BD BioSciences (San Diego, CA).  
2.2 EX VIVO ECTOCERVICAL TISSUE CULTURE 
Normal cervical tissue was obtained from the University of Pittsburgh Health Sciences Tissue 
Bank (Pittsburgh, PA) via surgical resection from women undergoing routine hysterectomies 
(IRB PRO09110431), or procured from a donor tissue to the National Disease Research 
Interchange (NDRI, Philadelphia, PA). The median age of donors was 42 years old (range 27-
50).   
Cervical tissue specimens were processed into explants of 5mm in diameter of epithelium 
and approximately 4mm in thickness encompassing the lamina propria. All experiments were 
performed in duplicate. Explants were polarized for culture on a 12mm transwell insert with the 
epithelial layer oriented apically, the basolateral layer oriented basally, and the stromal edges 
sealed by MatrigelTM Basement Membrane Matrix (BD BioSciences, San Jose, CA).  
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2.3 HORMONE PREPARATION 
Medroxyprogesterone 17-acetate (MPA; Sigma-Aldrich, St. Louis, MO) was dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 50,000µM and stored in aliquots at -20°C until 
ready for use. Explants were cultured for 48 hours at 37°C 5% CO2 in phenol-red free Dulbecco's 
Modification of Eagle's Medium cervical media supplemented with 10% charcoal-treated human 
A/B serum (to control for exogenous hormone exposure), 1% Penicillin/Streptomycin/L-
glutamine, and 1% nonessential amino acids in the basolateral compartment of the transwell 
exposing only the explant’s basolateral layer to hormone. Controls were cultured in media 
without MPA, while other explants were cultured with the indicated MPA concentrations. The 
explant culture supernatants were collected from the basolateral compartment at the 48-hour 
time-point then and stored at -80°C.  
2.4 HIV-1 INFECTION 
After the 48 hours, each explant was infected apically with either 5×102 or 5×103  TCID50 (tissue 
culture infectious dose for 50% infectivity) HIV-1BaL and incubated for 24 hours at 37°C 5% 
CO2, then washed with an isotonic saline solution to remove excess virus. Basolateral 
supernatants were collected again after 24 hours, and replenished with fresh medium containing 
equivalent amounts of MPA every 3-4 days up to 21 days of culture. Supernatant collections 
were kept frozen at -80˚C until p24 could be quantified using the Alliance HIV-1 enzyme-linked 
immunosorbent assay (ELISA) kit (Perkin Elmer, Waltham, MA). 
 11 
2.5 CYTOKINE EVALUATION 
Basolateral supernatant collections after explant incubation for 48 hours in the designated control 
media, or MPA-containing media were evaluated for cytokine analyte expression using the 
Milliplex Human Cytokine/Chemokine 9-plex Magnetic Bead Kit (Millipore Corp., St. Charles, 
MO). All samples were run in duplicate for the following analytes: GM-CSF, IFN-γ, IL-12 
(p40), IL-1β, IL-6, IL-8, IP-10, MIP-1β, TNF-α. Expression was measured using the Luminex 
MAGPIX system with xPONENT software V4.2.1324.0 (Luminex Corporation, Austin, TX).  
2.6 PBMC PREPARATION 
Whole blood was obtained from Central Blood Bank (Pittsburgh, PA) then processed for 
isolation of peripheral blood mononuclear cells (PBMCs). PBMCs were incubated at 2×106 
cells/mL for 72 hours at 37°C 5% CO2 in phenol-red free RPMI-1640 PBMC medium 
supplemented with 10% heat-inactivated charcoal-treated fetal bovine serum (FBS) and 1% 
Penicillin/Streptomycin/L-glutamine, plus one of the following treatments: a negative control, a 
positive control containing 1,000 U IL-2 and 5µg/mL PHA-P, or MPA at the indicated 
concentrations. After 72 hours, PBMCs were washed for flow cytometry at an optimal 
concentration of 6-12×106 cells/mL. 
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2.7 FLOW CYTOMETRY 
Cells were prepared for flow cytometry analysis of surface protein expression using the 
following antibodies: CD3 – Pacific Blue, CD4 – Alexa Fluor 700, CCR5 – PE, CXCR4 – PerCP 
Cy 5.5, CD69 – PE-Cy7, HLA-DR – FITC, α4β7 – APC (BD BioSciences, San Jose, CA). 
Viability staining was done using LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit, for 405 nm 
excitation (Invitrogen/ThermoFisher, Eugene, OR). Cell surface expression of antibodies was 
performed using a BD LSRII flow cytometer with 10,000 events per sample (BD BioSciences, 
San Jose, CA). Cell populations were gated from live, single cell population using fluorescence 
minus one (FMO) strategy (Figure 1). Data was extrapolated in FlowJo software (TreeStar 
Ashland, OR). 
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Figure 1. Flow cytometry gating strategy 
Live, single cell lymphocyte populations were gated using fluorescence minus one (FMO) strategy to 
isolate viable CD3+CD4+ double positive cells. 
 
 
2.8 STATISTICAL ANALYSES 
Cumulative p24 was calculated using the Virus Endpoint Calculator (AlphaStatConsult LLC, 
Damascus, Maryland) and compared between groups using a nonparametric Kruskal-Wallis test 
CD
3 
Viability 
CD
3 
CD4 
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and post-hoc Dunn’s test. Significance was defined as α=0.05 in GraphPad Prism 5 (GraphPad 
Software, San Diego California USA, www.graphpad.com).   
Flow cytometry analysis was performed using Kruskal-Wallis test and post-hoc Dunn’s 
test to compare median differences between percent positive cell populations. All flow cytometry 
statistical analysis was performed in GraphPad Prism 5.  
Median differences in cytokine marker expression between treatment groups was 
analyzed by Generalized Estimating Equations (GEE) analysis to the untreated control in 
STATA/SE 14 significance level α=0.05.  
A linear mixed effects model with random intercepts was applied to compare p24 output 
between treatment groups over the course of 21 days. The amount of p24 was defined as the 
continuous outcome, hormone concentration was defined as a fixed effect, day of collection was 
defined as a repeated measure, and each tissue was defined as a random factor. Separate models 
were applied to each viral titer. A Test of Fixed Effects was applied to evaluate the significance 
of fixed effects on the outcome in STATA/SE 14 significance level α=0.05.  
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3.0  RESULTS 
3.1 LOW-DOSE MPA EXPOSURE SUGGESTS VIRAL ENHANCEMENT, WHILE 
HIGH-DOSE MPA EXPOSURE SUGGESTS VIRAL SUPPRESSION 
3.1.1 Viral replication 
Polarized ectocervical tissue explants were treated with MPA concentrations (0.05nM-500µM) 
and subsequently infected with HIV-1 to determine if exogenous progestins impact viral 
replication. Viral replication was similar over the course of 21 days and was independent of viral 
infectious titer, where supraphysiologic concentrations of MPA suppressed viral replication and 
physiologic concentrations of MPA demonstrated a slight viral enhancement as compared to the 
untreated control explants. The amount of p24 measured for tissues treated with the lowest MPA 
concentrations (0.05nM-5nM) and infected with a 5×103 TCID50 of HIV-1 produced more or 
equivocal amounts of virus compared to the MPA-free control throughout the duration of culture 
(Figure 2A). Similarly, p24 output for tissues treated with the highest concentrations of MPA 
(5µM-500µM) remained below the control for 21 days of culture (Figure 2B). When explants 
were infected with a 5×102 TCID50 viral titer, the difference in viral replication was more 
defined. Viral output for tissues treated with 5nM-500nM of MPA remained above the MPA-free 
control, while tissues treated with concentrations well above physiologic levels (5µM-500µM) 
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displayed less viral replication compared to the control (Figure 2C). Overall for both viral titers, 
there was a consistent pattern of viral suppression compared to the control for supraphysiologic 
concentrations of hormone at 500µM and 5µM. In addition, lower concentrations of MPA at 
5nM and below physiologic concentrations showed slight viral enhancement compared to the 
control.  
 Stock hormone was dissolved in DMSO, added to cervical media to make the 500µM 
MPA solution, and then serially diluted in cervical media to achieve lower hormone 
concentrations. We evaluated the effects of DMSO on viral growth by including a DMSO 
control, where it was added to cervical media (without MPA) at concentrations comparable to 
the amount of DMSO used for the 500µM MPA. We noticed minimal HIV-1 replication in the 
DMSO control compared to the negative control, and that resembled viral growth at the 500µM 
MPA concentration (Appendix Figure 1 and 2). Although only one tissue was used for this 
evaluation thus far (n=1), this suggests DMSO may influence replication as lower concentrations 
of hormone contain successively less DMSO than the preceding concentration. Improvements to 
this model would include verifying that all hormone concentrations also contain the same 
amount of DMSO. 
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Figure 2. Viral growth and 95% CI 
Viral growth over time is represented by median concentrations of p24 in explant supernatant collected 
after incubation for 48 hours with either 500µM, 5µM, 500nM, 5nM, 1nM, 0.5nM, or 0.05nM MPA, then 
infected with (A) 5×103 TCID50 HIV-1BaL (n=5), (B) 5×103 TCID50 HIV-1BaL (n=12), or, (c) 5×102 
TCID50 HIV-1BaL (n=10). Error bars represent the 95% CI. 
 
3.1.2 Cumulative viral growth 
A different analysis comparing cumulative p24 produced during culture against other treatment 
groups recapitulates the results using the raw HIV-1 replication curves (Figure 3). There was a 
negative trend of decreasing viral replication with increasing MPA concentration for both viral 
infection titers. Tissues treated with 5nM and infected with 5×102 TCID50 HIV-1BaL showed 
greater absolute differences in median cumulative p24 compared to those infected with 5×103 
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TCID50 HIV-1BaL (Figure 3A and 3B). Interestingly, explants treated with 500nM MPA 
suggested viral enhancement when infected with a lower viral titer (Figure 3A), but suppression 
when infected with a higher viral titer (Figure 3B).  Higher concentrations of hormone at 5µM 
and 500µM portrayed less cumulative p24, again suggesting viral suppression while lower 
concentrations remained above or near the median control for the lowest concentrations of MPA 
(Figure 3A and 3B). Overall significance was only detected for the 5×102 TCID50 infections 
(Figure 3A, P=0.0125), but could not be attributed to any single pairwise comparison. 
Physiologic concentrations of hormone did not have an effect on viral replication (Figure 3C, 
P=0.0670). Overall, the differences in cumulative p24 were not significant for the 5×103 TCID50 
infections (Figure 3B, P=0.7932; Figure 3C, P=0.0670).  
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Figure 3. Cumulative p24 
Cumulative p24 is represented for 6 collection days after incubation for 48 hours with either 500µM, 5µM, 
500nM, 5nM, 1nM, 0.5nM, or 0.05nM MPA, then infected with (A) 5×102 TCID50 HIV-1BaL (n=10), (B) 
5×103 TCID50 HIV-1BaL (n=12), or (C) 5×103 TCID50 HIV-1BaL (n=5). Cumulative median p24 was 
compared to the control group using a Kruskal-Wallis ANOVA, and pairwise comparisons made to the 
Control group using Dunn’s test. Error bars represent the 95% CI. 
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3.1.3 Linear mixed effects model 
An evaluation of HIV-1 replication over time compared to a given MPA concentration portrayed 
a trend of suppression in viral growth for higher concentrations of MPA (Table 1). In a linear 
mixed effects model supraphysiologic concentrations (500µM) portrayed significant viral 
suppression over time shown by a negative difference in the slope compared to the control 
(P=0.025, P<0.001). The lowest concentration of MPA (5nM) portrayed significant viral 
enhancement over time only for the lower titer (5×102 TCID50 HIV-1BaL, P=0.005). In support of 
the 5×102 TCID50 viral replication (Figure 1A and 1B), tissues treated with a physiologic 
concentration of MPA (5nM) had greater predicted p24 values compared to the untreated tissues. 
For a given low MPA concentration (0.05nM-5nM), there was a trend of viral enhancement 
indicated by positive, increasing slopes as hormone concentration decreases, although none were 
significant. Using the 5×102 TCID50 HIV-1 may show a better association between physiologic 
MPA concentrations and viral enhancement. 
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Table 1. Viral growth in cervical tissue treated with medroxyprogesterone acetate (MPA) 
  Treatment 
group 
Slope 
difference (Δ) 
P-value 
5×102 TCID50HIV-1BaL (n=10)       
  MPA 500µM -0.618 P=0.025* 
  MPA 5µM -0.375 P=0.173 
  MPA 500nM +0.205 P=0.519 
  MPA 5nM +0.899 P=0.005* 
5×103 TCID50HIV-1BaL (n=12)     
  MPA 500µM -1.264 P<0.001* 
  MPA 5µM -0.645 P=0.003* 
  MPA 500nM -0.212 P=0.355 
  MPA 5nM +0.285 P=0.214 
5×103 TCID50HIV-1BaL (n=5)    
 MPA 5nM -0.068 P=0.820 
 MPA 1nM +0.416 P=0.166 
 MPA 0.5nM +0.484 P=0.107 
 MPA 0.05nM +0.526 P=0.080 
In a linear mixed effects model analyzing viral growth over time for a given MPA concentration, 
supraphysiologic concentrations (500µM, 5µM) again portrayed significant suppression over 
time shown by a negative significant difference in the estimate of the fixed effect compared to 
the control. In addition, the lower concentrations of hormone trended towards enhancement of 
viral replication over time (for a higher viral titer).   
 
3.2 CYTOKINE EXPRESSION 
The cytokine profile was analyzed using supernatants collected from pre-infected tissues 
cultured in their respective supraphysiologic MPA-containing media for 48 hours, a decrease in 
pro-inflammatory cytokines compared to the negative control (Table 3) was observed. For the 
analytes, there was a trend of decreasing cytokine expression as MPA concentration increased 
(Figure 4). Expression levels of IL-12, IL-6, and IL-8 indicate significant dose-dependent 
suppression (Table 3; P<0.005, P<0.05). Supraphysiologic MPA concentrations pointed to 
immunological suppression but as it approached more physiologic MPA concentrations 
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(0.05nM) the suppressive effects diminished. Interestingly, IP-10 expression levels only peaked 
at 1,041.32±1,074.92pg/mL for 1nM of MPA (Table 3). In addition, levels of GM-CSF did have 
an inverse trend but only pointed to significant upregulation at physiologic concentrations. GM-
CSF expression at 1nM and 0.05nM were significantly greater than the control, while that at 
0.5nM was not (Table 3).  
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Table 2. Median cytokine production from cervical tissue treated with medroxyprogesterone acetate (MPA) 
Cytokine Marker (pg/mL ± standard deviation) 
GM-CSF IFN-γ 
IL-12 
(p40) IL-1β IL-6 IL-8 IP-10 MIP-1β TNFα 
Control 
(no PHA-P / IL-2) 
(n=10) 
11.93
±17.35 
13.60
±10.47 
16.16
±11.04 
2.47
±3.00 
16,728.83
±13,607.76 
48,321.72
±54,587.44 
207.61
±5,242.71 
41.02
±36.07 
5.65
±5.72 
MPA 500µM 
(n=6) 9.13 ±4.67 
3.77 
±0.84 
*** 
6.55 
±3.22 
** 
1.08 
±0.52 
*** 
5,422.40 
±2,120.70 
*** 
12,567.65 
±6,845.53 
36.19 
±57.57 
16.12 
±16.06 
3.89 
±1.23 
MPA 5µM 
(n=7) 10.47 ±9.83 
4.25 
±76.30 
** 
8.57 
±4.32 
1.79 
±5.62 
** 
5,443.38 
±5,918.30 
*** 
18,307.99 
±14,912.19 
34.12 
±8,771.21 
21.00 
±164.22 
3.89 
±11.52 
MPA 500nM 
(n=7) 8.08 ±2.62 
6.31 
±4.45 
*** 
8.43 
±4.12 
1.64 
±0.61 
** 
5,095.41 
±6,189.42 
*** 
18,631.52 
±12,420.24 
54.72 
±459.06 
23.83 
±17.51 
3.64 
±1.28 
MPA 5nM 
(n=9) 10.76 ±7.37 
6.93 
±5.23 
15.84 
±11.69 
2.65 
±1.08 
*** 
9,674.22 
±11,239.56 
*** 
26,905.63 
±42,809.81 
71.37 
±1,887.41 
31.00 
±20.40 
4.79 
±3.97 
MPA 1nM 
(n=3) 
** 
12.36 
±2.36 
16.66 
±6.66 
30.35 
±0.35 
3.68 
±.685 
24,803.06 
±4,803.061 
*** 
69,380.63 
±9,380.631 
1,041.32 
±,041.323 
69.50 
±9.50. 
16.42 
±6.42 
24 
MPA 0.5nM 
(n=3) 18.87 ±31.46 
14.45 
±11.79 
30.34 
±4.01 
4.36 
±1.72 
34,350.70 
±21,897.02 
*** 
84,752.75 
±51,274.47 
538.61 
±305.59 
69.26 
±24.27 
14.83 
±8.49 
MPA 0.05nM 
(n=3) 
** 
44.72 
±32.20 
17.16 
±7.60 
31.07 
±2.53 
43.78 
±0.70 
25,720.46 
±12,863.82 
*** 
88,723.13 
±36,457.71 
799.12 
±220.00 
54.35 
±9.87 
11.10 
±4.08 
Summary of median cytokine values (pg/mL) and standard deviation from the 48-hour time point collections, before infect. P-values are 
representative of concentration group comparisons to the control in GEE analysis. 
** P<0.05, ***P<0.005 
Table 2 Continued
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Figure 4. Cytokine production from ectocervical tissue 
Cytokine production from cervical tissues treated with Medroxyprogesterone acetate (MPA). The data 
shown are the percent of control.  
 
3.3 HIGH-DOSE MPA IS ASSOCIATED WITH IMMUNE SUPPRESSION 
To define changes in cell activation and HIV-1 receptor expression on T cells, PBMCs were 
utilized initially rather than tissue to evaluate several log10 concentrations of MPA. Once 
identified, tissue will be treated with those MPA concentrations to determine if tissue-associated 
immune cells respond in a consistent manner. An investigation of T cell surface markers after 
PBMC treatment with high-dose MPA shows immune suppression with the reduction in 
activation. Compared to the negative, non-activated control, MPA at 50µM and 500µM 
decreased the percentage of CD4+ T cells that were positive for HLA-DR (4.04%±2.49 versus 
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1.06%±1.65 and 1.41% ± 0.63, respectively) (Table 2). While the differences were small and not 
significant, there was a 3.4-fold increase in the percentage of CD3+/CD4+ T cells positive for 
CCR5 when treated with 5µM MPA as compared with the negative control (Table 2).  
 
 
Table 3. Peripheral blood T cell marker expression after treatment with 
medroxyprogesterone acetate (MPA) 
 
Percent 
of live, 
CD3+ cells 
Percent of CD4+ T cells 
Sample (n=5) %CD4+ % CCR5+ 
% 
CD69+ 
% 
CXCR4+ 
% 
HLA-
DR+ 
% 
α4β7+ 
Control (no PHA-P / IL-2) 31.80% ± 11.61 
0.13% ± 
0.14 
5.33% ± 
3.77 
97.7% ± 
4.36 
4.04% 
± 2.49 
12.50% 
±3.83 
Control (with PHA-P/IL-2) 12.80% ± 11.77 
0.08% ± 
0.10 
61.30% 
± 4.03 
92.90% 
± 17.65 
30.60% 
± 9.73 
8.40% 
± 3.74 
MPA 5µM 35.90% ± 19.34 
0.45% ± 
0.64 
7.93% ± 
6.43 
93.80% 
± 9.02 
3.03% 
± 2.10 
8.22% 
± 1.97 
MPA 50µM 44.60% ± 15.93 
0.19% ± 
0.13 
5.73% ± 
6.11 
93.50% 
± 4.84 
1.06% 
± 1.65 
7.37% 
± 1.63 
MPA 500µM 44.60% ±16.60 
0.22% ± 
0.12 
8.78% ± 
6.08 
92.60% 
± 2.05 
1.41% 
± 0.63 
7.32% 
± 1.94 
P-values 0.5493 0.1126 0.4489 0.2049 0.1378 0.7380 
Median percent positive of parent populations with standard deviation. A Kruskal-Wallis ANOVA 
compared medians of each surface marker group to the negative control. The activated control with 
PHA-P/IL-2 was not included in the statistical analysis.  
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4.0  DISCUSSION 
Low, physiologic concentrations of DMPA did not significantly affect HIV-1 replication over 
time in ectocervical tissue ex vivo, while high concentrations that are not representative of 
physiologic levels suppressed HIV-1 replication. Tissues treated with supraphysiologic 
concentrations of MPA had reduced production of pro-inflammatory cytokines as well. PBMC 
treatments with similar high concentrations of MPA decreased expression of cellular activation 
markers. These data suggest that supraphysiologic concentrations of MPA likely act through the 
GR causing immune suppression while physiological concentrations of MPA do not. 
Despite the suggestive epidemiologic association between DMPA use and HIV-1 
acquisition, an updated WHO guideline reiterates the use of DMPA in resource poor countries 
[23]. While many cite that discontinuation of DMPA without a comparable replacement in at-
risk populations would impose more harm than benefit by increasing mother/child morbidity and 
mortality [23-24], identifying the factors that contribute to the relationship would decrease HIV-
1 incidence from the appropriate source. Furthermore, methodology from secondary analyses has 
limitations on the association of DMPA on HIV-1 risk, for example self-reported usage, 
inconsistent hormone exposures among users (i.e. contraceptive switching), unspecified DMPA 
formulation types (intramuscular dosage versus subcutaneous dosage), controlling for, “time-
varying confounders,” (i.e. coital frequency, condom use frequency), or controlling for personal 
exposure risk to HIV-1 [40]. These variables may confound the effect DMPA has on acquisition 
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risk. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial is projected to 
complete data collection in 2019 and prospectively evaluates HIV-1 incidence between four 
randomized arms of contraceptive use, including DMPA, levonorgestrel implant (a long-acting 
reversible progestin-based implant), and copper IUD [41]. Results from this trial will supplement 
current literature by prospectively investigating risk (rather than secondary analyses) while 
controlling for age, contraceptive switching, HSV-2 status, and disease progression in HIV-1 
seroconverts.  
As serum progestin levels peak to 2nM approximately 4 days after dosage [13], the risk 
association noted in observational studies could point to the long drug tail as a window of 
infection opportunity. Supraphysiologic doses of hormone (500nM to 500µM) showed HIV-1 
suppression over time and led to a reduction in pro-inflammatory chemokine/cytokine expression 
and CD4+ T cell activation markers. The use of DMSO, which can be toxic in tissues at high 
doses as used in the supraphysiologic MPA doses, for hormone dilutions also appeared to 
suppress HIV-1 replication but will require additional testing for a complete evaluation. When 
MPA was applied to the ectocervical tissue at physiologic concentrations (0.05nM to 5nM), 
trends toward increased HIV-1 replication was noted as seen with higher p24 levels when 
compared to the untreated control tissue. These data are consistent with relative HIV-1 infection 
differences noted in non-activated PBMCs treated with MPA ranging from 0.007nM-7nM [42]. 
While differences in HIV-1 infection of the PBMCs were significantly enhanced at physiologic 
concentrations of MPA (approximately 5.0 times greater at 0.7nM than the MPA-free control), 
initial infection was done using 100ng of p24 and using whole PBMCs instead of vaginal or 
cervical-sourced cells or tissue [42]. The results presented here suggest the minimal increase in 
viral replication at physiologic concentrations does not support MPA as the sole cause of 
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increased HIV-1 susceptibility. In conjunction with the viral infection data, no significant 
changes in HIV-1 coreceptors such as CCR5 or CXCR4 and cell activation markers were noted 
in PBMCs evaluated here. It would be of interest to investigate physiologic MPA concentrations, 
which resulted in modest increases in HIV-1 infection of ectocervical tissue, on the impact of 
mucosal T cell expression of CCR5 and their activation. 
Pro-inflammatory cytokine expression exhibited a dose-dependent pattern where 
increasing hormone concentrations above physiological concentrations were associated with 
decreasing expression of pro-inflammatory cytokines compared to the control. These data were 
consistent with previous gradual relative suppression of IL-6 and IL-8 [38] ranging from 0.1nM 
MPA to 100nM MPA, whereas supraphysiologic concentration of 100nM and 1000nM were 
significantly decreased compared to the 1nM reference dose [39]. The opposite effect was seen 
for relative expression levels in vaginal epithelial cells for TNFα, GM-CSF, MIP-1β, IL-6 and 
IL-8 when dosed with MPA ranging from 0nM to 390µM, but cultured for five days, which does 
not capture MPA concentrations in the drug tail [21]. Consistent with our results, IP-10 
production has been demonstrated to increase with a 1-log decrease in MPA concentration, but 
nonetheless at high physiologic concentrations of 100nM and 10nM [5, 43]. Additionally, 
expression levels at supraphysiologic concentrations of MPA (10nM – 1,000nM) for IFN-γ, GM-
CSF, MIP-1β, and TNF-α in PBMCs followed a similar concentration dependent pattern [43]. 
IL-10 expression in ectocervical cells at closer to physiologic hormone concentrations of 0.01nM 
to 1nM leads to a smaller decrease in IL-10 mRNA than that between 1nM to 100nM, likely 
indicating that as MPA concentration approaches the physiologic range the immunosuppressive 
effects are reduced [18]. Furthermore, the cytokine profile of basolateral supernatants from 
genital epithelial cells (GECs) after MPA exposure and after viral exposure was elevated for pro-
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inflammatory cytokines TNF-α, IL-1β, GM-CSF and chemokines IL-8, IP-10, MIP-1β [20], 
indicating the primary epithelial cells were producing a pro-inflammatory milieu that could 
promote HIV-1 infection.  
With the expression of pro-inflammatory cytokines showing enhancement at physiologic 
concentrations of MPA [38-39], GR engagement or sexually transmitted infection (STI) 
exposure may be potential mechanisms influencing HIV-1 acquisition. It’s been demonstrated 
that MPA at 1µM regulates IL-12 production via recruitment of the GR to the IL-12 promoter 
[18]. Our data show upregulation of pro-inflammatory cytokines at concentrations of 1nM and 
below, investigating GR engagement at these levels would provide insight whether this increase 
in cytokines is also mediated via the GR. Furthermore, HSV-2 seropositive populations have 
significantly higher HIV-1 seroconversion incidence rates (HR 4.6 [2.8–7.6]) than those who are 
HSV-2 negative [44-45]. This is further enhanced by DMPA use where seropositive HSV-2 
DMPA users are more likely to seroconvert to HIV-1 (HR 2.01 [1.12–3.63]) than NET-EN users 
[10]. With approximately 50% of persons infected with HSV-2 in South African countries that 
also have a high HIV-1 prevalence [46], this may point to another factor driving the 
epidemiologic association between HIV-1 acquisition risk and DMPA use. HSV-2 increases the 
percentage of α4β7+ CD4 T cells via enhancement of retinoic acid secretion by dendritic cells; 
this increase is typically co-upregulated with CCR5 expression and creates a highly susceptible 
environment for HIV-1 infection [47]. Another reason that may explain why physiologic 
concentrations of MPA had minimal effects on HIV-1 infection in our model could be attributed 
to the superficial epithelium sloughing off after 3 days in cultures [48]. A recent paper 
demonstrated that MPA increased epithelial permeability by reducing the expression of cell 
adhesion molecules and allowing entry of luminal microbiota and possibly viruses as well [33]. 
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Some of the limitations to this work included the use of surgical cervical resections from 
donors with a median age of 42 years (range from 27-50). While the epidemiologic association 
was noted in relatively younger groups of women, progesterone receptor expression in the uterus 
varies during different stages of the menstrual cycle but resembles early proliferative phase 
levels or lower post menopause [49], which could have implications in the baseline expression 
level in the cervical tissues used here and its effect on receptor engagement. Furthermore, limited 
demographic data was collected from donors, especially those related to previous exposure to 
hormone therapy, chemotherapy, or biological factors preceding the surgery. Future 
investigations would evaluate the influence of GR engagement by incorporating a GR antagonist, 
for example, and integrating HSV-2 into our ex vivo model.  
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APPENDIX: EVALUATION OF LOW-DOSE MPA ON LOW TITER HIV-1 
REPLICATION 
Figure 5. Appendix, Viral growth at low-dose MPA. 
Viral growth and 95% CI is represented in terms of the amount of p24 for 6 collection days after 
incubation for 48 hours with either 5nM, 1nM, 0.5nM, or 0.05nM MPA, then infected with 5×102 
TCID50 HIV-1BaL (n=1). The DMSO control in this experiment was added in concentrations 
comparable to the amount of DMSO added to 500µM MPA group (see Figure 2 and 3). 
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Figure 6. Appendix. Cumulative p24 at low-dose MPA. 
Cumulative median p24 is represented for 6 collection days after incubation for 48 hours with 
either 5nM, 1nM, 0.5nM, or 0.05nM MPA, then infected with 5×102 TCID50 HIV-1BaL (n=1). 
The DMSO control in this experiment was added in concentrations comparable to the amount of 
DMSO added to 500µM MPA group (see Figure 2 and 3).  
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